Comparing Docetaxel Plus Cisplatin with Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer: a Single Institute Study

Authors

  • adnan khosravi Assistant Professor of Internal Medicine, Hematology and Medical Oncology
  • Kian Khodadad Assistant Professor of Internal Medicine, Hematology and Medical Oncology, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease
  • Sharare Seifi Assistant Professor of Internal Medicine, Hematology and Medical Oncology, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease NRITLD, Masih Daneshvari Hospital,
  • Shirin Karimi Associate Professor of Pathology, Pathology Department, Mycobacteriology Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Zahra Esfahani-Monfared General Physician, Thoracic Oncology Department, Chronic Respiratory Disease Research Center, NRITLD, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:

Aims: The backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice. Methods: This single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage IIIB, IV) non-small cell lung cancer and Eastern Cooperative Oncology Group performance status of 0 to 2. They were randomly assigned by stratified blocks to receive Docetaxel/Cisplatin (DC, n=50) on day 1 or Paclitaxel/Carboplatin AUC 5 (PC, n=50) on day 1, every 3 weeks for up to six cycles. Primary end point was progression free survival (PFS); secondary end points were objective response rate, overall survival (OS) and toxicity. The administered dosage could be modified according to clinician’s discretion for each individual patient. Results: PFS was similar between DC and PC arms (4.5±0.3 v 4.6±1.8 months, respectively; HR= 1.337; 95% CI: 0.874 to 2.046, P= 0.181). Although median overall survival for DC arm was longer (17.2±4.4 m) than PC arm (10.6±0.7 m) but was not statistically significant (P=0.300). The 1-year survival rates were in favor of DC arm (53.1% v 37.9%). Objective response rates were similar in both groups. In our study, hematologic toxicity and neuropathy were more frequent in DC and PC arms, respectively. Conclusion: In our study two commonly used regimens of DC and PC showed statistically similar outcomes in terms of PFS and OS, albeit numerically results of OS and 1-year survival were in favor of DC arm.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

comparing docetaxel plus cisplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: a single institute study

aims: the backbone of treatment in advanced non-small cell lung cancer is platinum-based doublet chemotherapy. we intended to compare the effectiveness of two commonly used regimens in real world practice. methods: this single institute, parallel comparative post marketing study included 100 patients with chemo-naïve advanced (stage iiib, iv) non-small cell lung cancer and eastern cooperative o...

full text

Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer.

AIM Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m(2)) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m(2...

full text

Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non-Small Cell Lung Cancer

Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy administered as an adjuvant therapy after complete resection of non-small cell lung cancer. Methods: Forty-four patients (GC regimen, n = 29; PC regimen, n = 15) received gemcitabine at a dose of 1000 mg...

full text

Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer

Background: This retrospective study was to evaluate the efficacy and toxicity of gemcitabine plus carboplatin (GC regimen) and paclitaxel plus carboplatin (PC regimen) combination chemotherapy in elderly patients with non-small cell lung cancer. Methods: Seventy-four patients (GC regimen, n = 44; PC regimen, n = 30) received gemcitabine at a dose of 1000 mg/m2 on days 1 and 8, and carboplatin ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 13  issue 2

pages  575- 581

publication date 2014-06-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023